Janssen looks to turn PhIII win for Rybrevant in EGFR-mutated NSCLC into pressure on AstraZeneca blockbuster
Johnson & Johnson’s Janssen said Wednesday that its bispecific antibody Rybrevant (amivantamab-vmjw) in combo with lazertinib met its dual primary endpoints in a Phase III trial for patients with a type of non-small cell lung cancer.
The company touted the results as the first to show a statistically significant and clinically meaningful improvement in progression-free survival in the post-Tagrisso (osimertinib) setting. Janssen is looking to win over a chunk of the market currently held by AstraZeneca’s blockbuster Tagrisso, which is the first-line treatment for this setting, and generated sales of $5.4 billion in 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.